PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, ...
Pharma presented data from the ATTRibute-CM study, showing that acoramidis significantly reduces all-cause mortality, ACM, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈